AVPR1A
Vasopressin V1a receptor
As of the edition of 20 October 2026, AVPR1A (vasopressin V1a receptor, UniProt P37288) has 14 drugs tested at it and 19 companies on the list, 2 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P37288
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 7
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Hormones; Digestive system; Heart and blood vessels; Mental health; Infections; Nervous system
- Registered trials of its drugs
- 247
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 8 |
| Active | 1 |
| Went quiet | 3 |
| Stopped | 2 |
| Total | 14 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Desmopressin | Marketed | Phase 4 | none listed |
| Vasopressin | Marketed | Phase 4 | none listed |
| Terlipressin | Marketed | Phase 4 | Ends 2029 |
| Conivaptan | Marketed | Phase 4 | none listed |
| Balovaptan | Stopped | Phase 3 | none listed |
| SRX246 | Active | Phase 2 | none listed |
| Selepressin | Stopped | Phase 3 | none listed |
| Argipressin tannate | Marketed | Phase 4 | none listed |
| Pecavaptan | Went quiet | Phase 2 | none listed |
| SRX251 | Went quiet | Phase 1 | none listed |
| RO-5028442 | Went quiet | Phase 1 | none listed |
| Felypressin | Marketed | No phase stated | none listed |
12 of 14 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 2 |
| Engaged | 1 |
| Undetermined | 14 |
| Total on the list | 19 |
The other 16 companies at AVPR1A
In the product19 companies in all; 16 are not named here, and no score is.
See the 19 companies at AVPR1A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.